Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Akums Drugs and IPO
Price Band
₹646.0–679.0
Issue Size
₹1856.74 Cr
Lot Size
22 shares
Min Investment
₹14,938
GMP
+₹43.0 (6.33%)
Issue Price
₹679.0
Subject to Sauda
₹700
Paid only if allotted
Akums Drugs and IPO AI Summary
- Akums Drugs and IPO is listed on BSE, NSE in the Pharmaceuticals sector.
- Price band: ₹646.0–₹679.0 per share, lot size 22 shares (min. investment ₹14,938).
- Subscription window: 30 Jul–01 Aug 2024, listing on 06 Aug 2024.
- Current GMP is +₹43.0 (6.33%), an estimated listing price of ₹722 — unofficial and can change daily.
Akums Drugs and Pharmaceuticals Limited is a CDMO with a strong manufacturing base and a diverse product offering. While it has shown growth in revenue, recent profitability figures indicate challenges that potential investors should consider.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Akums Drugs and IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 01 Aug 2024 — not a current signal.
4 of 4 reviewers say Positive
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Akums Drugs and IPO Grey Market Premium (GMP) Today
GMP
+₹43.0
GMP %
+6.33%
Est. Listing
₹722.0
Updated: 25 Jul 2026 14:04
About the Company
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs). As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few. The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023). The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF). As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.
Company Financials (₹ Cr)
As of 2024-03-31
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| NET Worth | 709.50 | 717.19 | 621.98 |
| Reserves and Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
Key Ratios
NAV
₹49.59
ROE
0.11%
ROCE
3.37%
RoNW
-0.57%
P/B Value
13.69
PAT Margin
0.02%
Debt/Equity
0.69
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Innova Captab Limited | 145.2 | 11.35% | 29.91 | 18.66 | 18.66 |
| Mankind Pharma Limited | 233.73 | 20.43% | 44.65 | 47.75 | 47.68 |
| JB Chemicals | 188.37 | 18.9% | 51.38 | 35.66 | 34.85 |
| Eris Lifesciences Ltd | 190.12 | 15.16% | 34.95 | 28.82 | 28.79 |
| Alkem Laboratories Ltd | 862.46 | 17.41% | 34.18 | 150.19 | 150.19 |
| Torrent Pharmaceuticals Ltd. | 202.57 | 24.15% | 60.2 | 48.94 | 48.94 |
| Gland Pharma Limited | 483.41 | 8.85% | 42.45 | 46.9 | 46.89 |
| Suven Pharmaceuticals Limited | 80.56 | 14.64% | 69.54 | 11.8 | 11.8 |
| Divi's Laboratories | 511.21 | 11.79% | 74.99 | 60.27 | 60.27 |
| Akums Drugs and Pharmaceuticals Limited This IPO | 49.59 | -0.57% | — | -0.28 | -0.28 |
Promoters
Sanjeev Jain, Sandeep Jain and Akums Master Trust
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Repayment/prepayment of all or certain borrowings of our Company 159.91 2 Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited 227.09 3 Funding incremental working capital requirements of our Company 55.00 4 Pursuing inorganic growth initiatives through acquisitions 27.87 5 General corporate purposes 167.50
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹3,694.52 Cr in the year ending 31 Mar 2022, increasing to ₹3,700.93 Cr by 31 Mar 2023, and further rising to ₹4,212.21 Cr by 31 Mar 2024. This indicates a consistent growth in revenue over the periods.
Profit Trend
Profit After Tax was -₹250.87 Cr in the year ending 31 Mar 2022, improving to ₹97.82 Cr by 31 Mar 2023, and then decreasing to ₹0.79 Cr by 31 Mar 2024. This shows a recovery in profitability followed by a significant drop in the most recent period.
Valuation
Priced at roughly -2.43 trailing earnings based on the issue price, versus peers trading at a P/E range of 29.91 to 74.99.
Grey Market Premium, Explained
The grey market premium (GMP) is the price at which shares are traded in the unofficial market before they are listed on the stock exchange. A positive GMP indicates that the market expects the stock to perform well on its listing day.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against the company's growth potential and market position.
Who May Want to Wait
Investors who prefer stable earnings and low-risk investments may want to avoid this IPO due to its recent profitability challenges.
Listing Gains — The Risk
Listing-day gains can be unpredictable. While some IPOs may see a rise in stock price, others may not perform as expected. Investors should consider the overall market conditions and company fundamentals.
This evaluation is generated from Akums Drugs and's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Akums Drugs and IPO GMP today?
Akums Drugs and IPO GMP today is +₹43.0 (6.33%), indicating an estimated listing price of ₹722. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Akums Drugs and IPO?
The price band of Akums Drugs and IPO is ₹646.0–₹679.0 per share.
When does Akums Drugs and IPO open and close?
Akums Drugs and IPO opens on 30 July 2024 and closes on 01 August 2024.
When does Akums Drugs and IPO list on the stock exchange?
Akums Drugs and IPO listed on 06 August 2024 at ₹722.0.
What is the lot size for Akums Drugs and IPO?
The lot size for Akums Drugs and IPO is 22 shares, requiring a minimum investment of ₹14,938.
What is the price band for the IPO?
The price band for the IPO is ₹646 to ₹679.
What is the minimum investment required?
The minimum investment required is ₹14,938.
What is the lot size for the IPO?
The lot size for the IPO is 22 shares.
When does the IPO open and close?
The IPO opens on July 30, 2024, and closes on August 1, 2024.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of the shares in the unofficial market.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
30 Jul 2024
Close
01 Aug 2024
Allotment
02 Aug 2024
Listing
06 Aug 2024
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Akums Drugs and?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.